Head-to-head · WeighScore
Nouri vs Zealthy
The verdict
Nouri takes it — 54.8/100 to 46.7/100.
Nouri grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Nouri is a DTC telehealth platform offering compounded semaglutide and tirzepatide bundled with nutrition and movement planning plus clinician messaging — lifestyle support included rather than upsold.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Nouri | Zealthy |
|---|---|---|
| WeighScore | 54.8/100 | 46.7/100 |
| Grade | C | C |
| Scorecard rank | #455 | #496 |
| Semaglutide | Not disclosed | $286/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | Not disclosed | $351/mo (starting dose, plus a separate fee, compounded) |
| Coverage | All 50 states | 34 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #455 · C
Strengths
- Named clinical MSO partner (Wasef Health, PC; Michael Wasef, MD) with public contact email
- Named 503A compounding pharmacy partner (Jungle Jim's Pharmacy, Fairfield OH) with full address
- Available in all 50 states per the FAQ
- Flat per-dose pricing within each tier — no dose-escalation surcharge
- Nutrition and movement coaching included in the medication price
Where it loses points
- Compounded medications only — no FDA-approved Wegovy, Ozempic, Mounjaro, or Zepbound
- Operating entity name not disclosed in the Terms of Service
- Terms 'where we operate' language is slightly weaker than the FAQ's all-50-states claim
- Video visit required in some states, but those states aren't listed
- FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Graded #496 · C
Strengths
- Serves 34 states — meaningful nationwide footprint
- Asynchronous model removes friction for patients who don't want a video visit
- Independent licensed prescribers retain full clinical authority
Where it loses points
- Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
- Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
- Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
- Recently rebranded to Gronk Inc. amid active enforcement
- FDA issued this company a warning letter dated 1 September 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.